Definium Therapeutics, Inc. - 10-Q Filing
Definium Therapeutics reports Q3 2025 financial results featuring significant R&D and G&A expense activity and ongoing warrant liability valuations.
Tickers: $MNMD
More Regulatory news
- UNITED BANCORP INC /OH/ - 10-Q Filing
- PATRIOT GOLD CORP - 10-Q Filing
- First Digital Acquisition Corp Ltd. - 8-K Filing
- GROOVE BOTANICALS INC. - 10-Q Filing
- Johnson Controls International plc - 10-K Filing
- OLD NATIONAL BANCORP /IN/ - 8-K Filing
- AMTECH SYSTEMS INC - 8-K Filing
- REGIONAL HEALTH PROPERTIES, INC - 8-K Filing
- Bitwise Avalanche ETF - 8-K Filing
- MiNK Therapeutics, Inc. - 10-Q Filing